Retatrutide Near Me: Clinics, Pharmacies and Trial Sites

No pharmacy, clinic or med spa near you can legally give you retatrutide, because no approved version exists yet. The two legal routes to retatrutide near me are a Lilly trial site (as of October 2026, one fatty liver trial is recruiting at 137 US sites in 34 states) and expanded access that your own doctor requests. Lilly's October 2026 FAQ says it "has not been reviewed or approved by the FDA or any regulatory agency in the world, and no one can legally sell it for human use."

A clinic page with a city in the title doesn't change that, and "GLP-3 near me" searches (a nickname, see our GLP-3 guide) get the same answer.

Where can I get retatrutide near me?

Lilly's October 28, 2026 release says "Anyone purporting to sell retatrutide to consumers is breaking the law." That rules out every storefront.

A pharmacist can't fill a script for retatrutide even if a doctor writes one, because there's no product. Our where to buy retatrutide page compares every channel, how to get retatrutide covers the legal routes, and is retatrutide legal covers the law.

Trial sites recruiting now, by state

One Lilly retatrutide treatment trial is recruiting in the US: SYNERGY-Outcomes, a Phase 3 study in adults with fatty liver disease (MASLD) at higher risk of liver complications. We pulled its site list from ClinicalTrials.gov on October 31, 2026 (record last updated October 8). It listed 137 US sites recruiting, in 34 states, plus 4 more not yet recruiting.

Sites in the big cities

For retatrutide in San Antonio, the record lists 3 recruiting sites; Houston has 5, and Austin and New York City 3 each. Los Angeles and San Diego have 1 each, with the rest of California's 14 in towns like Long Beach, Pasadena and Fresno. Nashville has none: Tennessee's 2 sites are in Chattanooga and Cordova. Sites open and close, so check the live record first.

Who can join

Qualifying is the hard part. Entry needs age 18 or older, a BMI of at least 25, liver fat of 8% or more, and set ranges on a liver blood test (ELF score 9 to 10.8) and a stiffness scan (10 kPa or more, under 20). People with type 1 diabetes or an HbA1c above 10% are out. The trial has a retatrutide arm and a tirzepatide arm, each against placebo, and runs about 224 weeks, so getting in doesn't guarantee the active drug. Our fatty liver page covers the earlier liver-fat results.

The record lists Lilly's trial line as 1-877-CTLILLY (1-877-285-4559). The big obesity trials have finished enrolling; see our clinical trials page.

Our read: without fatty liver disease, a trial site near you is unlikely to be your route in 2026.

Clinics and med spas that advertise reta shots

The FDA says it has warned telehealth companies that marketed retatrutide, including directly to consumers, and outsourcing facilities that repackaged it. On August 12, 2026 Lilly filed 6 lawsuits against US compounding pharmacies, medical spas and online sellers, and referred more than 200 people and businesses to the FDA, the Justice Department, state attorneys general and licensing boards.

So a clinic offering reta injections is supplying something Lilly didn't make, and we couldn't find a regulator test of a US clinic's product. Ask any clinic three things: who made the drug, what its approval number is, and whether the clinic is a site in a Lilly trial. There's no approval number to give, and a trial site gives Lilly's drug only to enrolled participants.

Where do reta peptide vials near me come from?

Online sellers, friends and social media, going by the one regulator report we found on where people got them. In a June 19, 2026 alert, Victoria's health department reported 6 cases of acute liver injury since January 2026 in people who used products labeled retatrutide. It said a contaminant may be the cause and all such products are at risk.

Australia's TGA said on September 14, 2026 that a vial sold as retatrutide, tested after someone was hospitalized with a torn esophagus from vomiting, held no retatrutide. It held undeclared semaglutide at about 8 times the level in approved semaglutide products. If you're weighing a seller anyway, our page on retatrutide for sale covers what's listed online, and vetting a seller covers what a batch report can and can't prove.

Expanded access through your own doctor

Lilly's expanded access program (NCT07629401), listed as available as of its August 6, 2026 update, is for adults with a BMI of 35 or more despite adhering to the highest available dose of a long-term weight medicine, 2 or more serious or life-threatening obesity complications, and no way to join a trial. Your doctor calls the Lilly Answers Center at 1-800-545-5979; the listing asks patients not to call Lilly themselves. Availability depends on where you live, supply and Lilly's review of your case.

Approved options a local doctor can prescribe

Tirzepatide and semaglutide are sold at pharmacies now. As of October 31, 2026, LillyDirect lists self-pay Zepbound (tirzepatide) KwikPen or vials at $299 a month for 2.5 mg, $399 for 5 mg and $449 for higher doses if you refill within 45 days. NovoCare lists Wegovy pens up to 2.4 mg at $349 a month, with new patients paying $199 for the first 2 fills of the 2 starting doses through December 31, 2026. Our retatrutide price page has the full comparison, and Zepbound compared with retatrutide lines up the trial results.

On filing, Lilly last said, on September 29, 2026, that it plans to submit retatrutide to the FDA in the first quarter of 2027 as a Biologics License Application (BLA). On October 2, 2026, the FDA decided that retatrutide is a drug, not a biological product, so an application would need to be filed under section 505 of the Federal Food, Drug, and Cosmetic Act. Lilly's appeal on that question is pending in the Seventh Circuit, and we found no ruling as of October 31, 2026. A filing isn't an approval, and our FDA approval page tracks what comes next.